
INVESTIGATIONAL TECHNOLOGY PLATFORM
CELLULARSCIENCE FOR HEALTHSPAN RESEARCH
SCROLL TO EXPAND
Our MissionDeveloping investigational cellular technology for responsible healthspan research
Celljevity is developing investigational cellular technology, biomarker analysis tools, and research infrastructure for responsible longevity science.
A future where cellular aging biology is better understood through rigorous research, qualified medical governance, and transparent communication.
Learn MoreResearch Context


The Prometheus PlatformIn Development
Our investigational platform combines cellular science, biomarker analysis, and software infrastructure for responsible healthspan research.
Cellular Research
Study autologous cells and cellular-aging-associated markers through a proprietary research platform.
Biomarker Analysis
Organize cellular and biomarker data for qualified scientific and medical review.
Defined Workflow
Protocol timelines depend on provider assessment, laboratory workflow, and local requirements.
Research Applications
Exploratory work across cellular aging biology, inflammation pathways, tissue repair, and longitudinal biomarkers.
Research Workflow
The Investigational Workflow
From inquiry to laboratory and provider review in defined steps.
Tissue Collection
Where appropriate, sample collection is performed by licensed providers under applicable requirements
Cell Isolation
Fibroblasts may be isolated and expanded under controlled laboratory processes
Laboratory Protocol
A proprietary process is being studied for cellular-aging-associated markers
Quality Validation
Single-cell RNA sequencing may support cell-state characterization and quality review
Provider Review
Any clinical use is subject to licensed provider judgment and local regulation
Results & Monitoring
Biomarker and cellular data may be reviewed over time under applicable protocols
Timelines vary by provider assessment, protocol, laboratory workflow, and jurisdiction.
Learn MoreThe Science Behind Prometheus
Research Areas Under Review
Prometheus is an investigational platform studying autologous cells, epigenetic reprogramming, and biomarker analysis in cellular aging biology.
Public research references and publication counts should be reviewed with scientific and legal advisors before being used as substantiation.
Senolytics
Senescent cells are an active area of aging research. Celljevity reviews this biology as part of its investigational platform development.
Epigenetics
Epigenetic patterns are studied as markers of cellular state and aging biology within controlled research workflows.
Metabolism
Mitochondrial and metabolic markers may help characterize cell state in research settings.
Immunology
Immune and inflammatory signaling are reviewed as research areas, without implying clinical efficacy.
Clinical Collaboration Network
Provider-Led Collaboration
Celljevity coordinates research and technology collaborations. Any medical assessment, procedure, or follow-up is conducted by licensed providers where legally permitted.

Antibes, France
Clinique DelMar
Potential collaboration in France is subject to licensed provider oversight, local governance, and applicable regulatory review.
Under Evaluation
Global Expansion
Future regional collaborations are under evaluation and are not presented as operational treatment sites.
Prometheus Technology
Review Considerations (Educational Only)
Prometheus is an investigational cellular technology platform. This website does not determine eligibility or offer treatment.
Any clinical activity requires independent medical review, informed consent, and jurisdiction-specific legal and regulatory assessment.
Provider-Led Eligibility Review
Suitability cannot be determined from website content. Any clinical activity requires independent medical judgment and local regulatory review.
Criteria & Screening:
Adult inquiries only
Protocol-specific criteria
Independent provider assessment required
Protocol Considerations:
Adult status and informed-consent capacity
Independent review of medical history
Protocol-specific inclusion criteria
Protocol-specific exclusion criteria
Jurisdiction-specific legal and ethics review
Licensed provider determination
Eligibility depends on protocol-specific criteria and licensed provider review.
Learn About EligibilityRequest educational information about research context and provider-led review requirements.
Latest from Our Blog
Research stories, clinical insights, and platform updates
Explore the latest regenerative discoveries, clinic-ready playbooks, and product launch updates from the Celljevity platform.

Diederik van der Reijt - Celljevity: Pioneering the Future of Cellular Rejuvenation
CEO Diederik van der Reijt discusses Celljevity's vision for revolutionizing healthcare through cellular therapy and the company's ambitious growth plans.

Inclusive Healthcare: Celljevity's Mission to Broaden Access to Advanced Therapies
Celljevity's innovative approach to making advanced cellular therapies accessible to broader populations through strategic partnerships and global expansion.

Breakthrough in Cellular Reprogramming: How Celljevity's Prometheus Therapy Reverses Biological Aging
Revolutionary cellular reprogramming technology shows promising results in reversing biological aging markers and restoring cellular function.
Our Team
World-Class Leadership
Led by experienced executives and guided by distinguished advisors
Leadership Team
Rhys Tombling
Finance Director
London, England
Medical & Scientific Board
Dr. Henry Delmar
Founder, Clinic Del Mar
Nice, France
Dr. Pierre Maldiney
Cardiologist & Anti-Aging Physician
Paris, France
Dr. Lin Quan
Clinical Director, UCLA
Los Angeles, USA
Dr. Murat Bozkurt
Medical Advisor
Ankara, Turkey
Advisory Board
Neil Bush
Senior Advisor
Houston, USA
Rachid Bouzouba
Co-Founder, MCM Partners
Hong Kong
Shirin Azad
Strategic Advisor
Europe
Questions & Answers
Frequently Asked Questions
Educational information about Prometheus technology
Can't find what you're looking for? Contact our team
Treatment Process
Clinical & Scientific
Still have questions? Contact our specialist team
Contact UsImportant notice: Celljevity is a biotechnology company developing investigational cellular technology. Information on this website is educational only and is not medical advice, a treatment recommendation, or an offer to provide medical services. Celljevity technology is not approved by the FDA or EMA. Any clinical activity is subject to independent medical review, local regulation, and licensed provider oversight.
